Payment overview · 2025
General Payments
$352.65
15 reported records · 6 companies
Healthcare provider profile · identity verified
Harry S Sahi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEMOYNE, PA · NPI 1689720021
Verified facts
What the public records show
CMS Open Payments records show Harry S Sahi, MD received $352.65 in general payments during 2025 across 15 reported records.
ABBVIE INC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 549 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.87 | 26.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.57 | 24.3% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $82.68 | 23.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.39 | 15.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.36 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.78 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.65 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.87 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $85.57 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $82.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.39 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.39 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 549 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
549 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1202 | 229 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 110 |
| Eliquis | Apixaban | 549 | 46 |
| Furosemide | Furosemide | 445 | 69 |
| Potassium Chloride | Potassium Chloride | 436 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 419 | 78 |
| Sertraline Hcl | Sertraline Hcl | 406 | 48 |
| Lisinopril | Lisinopril | 334 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 327 | 56 |
| Gabapentin | Gabapentin | 306 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 39 |
| Metformin Hcl | Metformin Hcl | 250 | 49 |
| Simvastatin | Simvastatin | 226 | 45 |
| Losartan Potassium | Losartan Potassium | 220 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 56 |
| Mirtazapine | Mirtazapine | 216 | 23 |
| Donepezil Hcl | Donepezil Hcl | 210 | 24 |
| Carvedilol | Carvedilol | 198 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 186 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 35 |
| Warfarin Sodium | Warfarin Sodium | 177 | suppressed |
| Omeprazole | Omeprazole | 175 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 30 |
| Jardiance | Empagliflozin | 162 | 14 |
| Prednisone | Prednisone | 146 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 144 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 34 |
| Trazodone Hcl | Trazodone Hcl | 139 | 17 |
| Risperidone | Risperidone | 137 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 135 | suppressed |
| Famotidine | Famotidine | 129 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 17 |
| Buspirone Hcl | Buspirone Hcl | 114 | 12 |
| Xarelto | Rivaroxaban | 114 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 11 |
| Bumetanide | Bumetanide | 105 | 13 |
| Levetiracetam | Levetiracetam | 104 | 13 |
| Memantine Hcl | Memantine Hcl | 103 | 13 |
| Finasteride | Finasteride | 100 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 22 |
| Ezetimibe | Ezetimibe | 94 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | suppressed |
| Latanoprost | Latanoprost | 80 | suppressed |
| Tradjenta | Linagliptin | 79 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | 14 |
| Bupropion Xl | Bupropion Hcl | 73 | suppressed |
| Trulicity | Dulaglutide | 70 | suppressed |
| Allopurinol | Allopurinol | 66 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 63 | 11 |
| Alendronate Sodium | Alendronate Sodium | 62 | 12 |
| Lorazepam | Lorazepam | 59 | 15 |
| Spironolactone | Spironolactone | 59 | 11 |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 38 |
| Baclofen | Baclofen | 57 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 56 | 14 |
| Multaq | Dronedarone Hcl | 55 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 53 | suppressed |
| Amoxicillin | Amoxicillin | 52 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 18 |
| Ondansetron Odt | Ondansetron | 49 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 40 |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Levemir Flexpen | Insulin Detemir | 42 | suppressed |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 41 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Clonidine | Clonidine | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 11 |
| Nystatin | Nystatin | 34 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 11 |
| Digoxin | Digoxin | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 22 |
| Glipizide | Glipizide | 28 | suppressed |
| Klor-Con 8 | Potassium Chloride | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Brinzolamide | Brinzolamide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Lumigan | Bimatoprost | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Silodosin | Silodosin | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Glucagon Emergency Kit | Glucagon | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 17 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cefazolin Sodium-Dextrose | Cefazolin Sodium/Dextrose,iso | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ramelteon | Ramelteon | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Klonopin | Clonazepam | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.65 · 15 records | ABBVIE INC. | ACCRUFER, AREXVY, ELIQUIS, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error